Primary Record
Cabotegravir
Note: Only for scientific research or as raw materials for production.
- In stock
- 8,454 g
- Purity
- 99.2 %
- CAS
- 1051375-10-0
Compound Identifiers & Properties
- CAS
- 1051375-10-0
- PubChem CID
- 54713659
- SMILES
- C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- Canonical SMILES
- C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
Names & Synonyms
- Cabotegravir
- Apretude
- cabotegravirum
- 1051375-10-0
- Vocabria
- GSK744
- Cabotegravir sodium
- Apretude (TN)
- Vocabria (TN)
- GSK1265744
- GSK744 LAP
- GSK744 LA
- GSK1265744A
- UNII-HMH0132Z1Q
- Cabotegravir (Standard)
- Cabotegravir [USAN:INN]
- Cabotegravir(GSK744)
- GSK 744
- RefChem:573195
- GSK-1265744
- HMH0132Z1Q
- SureCN82803
- Cabotegravir (GSK744, GSK1265744)
- CABOTEGRAVIR [INN]
- CABOTEGRAVIR [JAN]
- GSK-1265744A
- D08LDB
- CABOTEGRAVIR [USAN]
- Cabotegravir and rilpivirine
- MFCD25976748
- S/GSK1265744
- SCHEMBL82803
- GSK-744LA
- CABOTEGRAVIR [WHO-DD]
- C19H17F2N3O5
- CHEBI:172944
- Cabotegravir (JAN/USAN/INN)
- orb1301075
- Cabotegravir; GSK1265744
- CHEMBL2403238
- SCHEMBL29374458
- GTPL11386
- DTXSID50146982
- GSK 1265744
- S-265744
- 744 LA
- WCWSTNLSLKSJPK-LKFCYVNXSA-N
- CABENUVA COMPONENT CABOTEGRAVIR
- CABOTEGRAVIR [ORANGE BOOK]
- GLXC-90529
- AMY27899
- BCP08631
- EX-A2330
- GSK744 (S/GSK1265744)
- BDBM50492496
- EBC-26970
- HY-15592R
- s7766
- ZINC96927633
- AKOS027253403
- S/GSK-1265744
- ACN-041362
- Cabenuva (cabotegravir + rilpivirine)
- CCG-268708
- CS-5078
- DB11751
- CID11965164
- NCGC00386434-02
- AC-30895
- AS-61279
- CID 11965085
- DA-71856
- FD143198
- HY-15592
- S/GSK1265744; GSK744
- SY099595
- A8566
- NS00073130
- J3.144.828J
- A16014
- D10548
- P14046
- EN300-7388992
- A902375
- (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
- (3S,11AR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- CAB
- Q15411012
- B0084-463362
- (3S,11aR)-N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
- (3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
- (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0,3,7]trideca-9,12-diene-12-carboxamide
- (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide
- (3S)-N-(2,4-Difluorobenzyl)-2,3,4,6,9,9aalpha-hexahydro-5-hydroxy-3-methyl-4,6-dioxo-1-oxa-3a,8a-diaza-1H-benzo[f]indene-7-carboxamide
- (3S,11AR)-3-METHYL-5,7-DIOXO-2,3,5,7,11,11A-HEXAHYDROOXAZOLO[3,2-A]PYRIDO[1,2-D]PYRAZINE-8-CARBOXYLIC ACID
- (3S,11aR)-N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
- (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8 -carboxamide
- (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2- d]pyrazine-8-carboxamide; (3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2- d]pyrazine-8-carboxamide; Apretude; GSK 1265744A; GSK 744; (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide
- (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido [1,2-d]pyrazine-8-carboxamide
- (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- 1264720-72-0
- GSK-1265744|||(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide|||S-265744
- N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
- N-(2,4-Difluorobenzyl)-3alpha-methyl-4,6-dioxo-5-hydroxy-2,3,4,6,9,9aalpha-hexahydro-1-oxa-3a,8a-diaza-1H-benzo[f]indene-7-carboxamide
- OXAZOLO(3,2-A)PYRIDO(1,2-D)PYRAZINE-8-CARBOXAMIDE, N-((2,4-DIFLUOROPHENYL)METHYL)-2,3,5,7,11,11A-HEXAHYDRO-6-HYDROXY-3-METHYL-5,7-DIOXO-, (3S,11AR)-
- Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; (3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; Cabotegravir; GSK 1265744A; GSK 744; GSK 1265744A
- Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-